- Home
- EMCG vs CMRX Comparison
EMCG vs CMRX Comparison
Compare EMCG & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- CMRX
- Stock Information
- Founded
- EMCG 2021
- CMRX 2000
- Country
- EMCG United States
- CMRX United States
- Employees
- EMCG N/A
- CMRX N/A
- Industry
- EMCG
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- EMCG
- CMRX Health Care
- Exchange
- EMCG NYSE
- CMRX Nasdaq
- Market Cap
- EMCG 83.7M
- CMRX 77.0M
- IPO Year
- EMCG 2022
- CMRX 2013
- Fundamental
- Price
- EMCG $11.60
- CMRX $0.93
- Analyst Decision
- EMCG
- CMRX Strong Buy
- Analyst Count
- EMCG 0
- CMRX 1
- Target Price
- EMCG N/A
- CMRX $11.00
- AVG Volume (30 Days)
- EMCG 3.2K
- CMRX 119.4K
- Earning Date
- EMCG 01-01-0001
- CMRX 11-08-2024
- Dividend Yield
- EMCG N/A
- CMRX N/A
- EPS Growth
- EMCG 186.72
- CMRX N/A
- EPS
- EMCG 0.24
- CMRX N/A
- Revenue
- EMCG N/A
- CMRX $144,000.00
- Revenue This Year
- EMCG N/A
- CMRX $3,040.12
- Revenue Next Year
- EMCG N/A
- CMRX N/A
- P/E Ratio
- EMCG $48.18
- CMRX N/A
- Revenue Growth
- EMCG N/A
- CMRX N/A
- 52 Week Low
- EMCG $10.84
- CMRX $0.75
- 52 Week High
- EMCG $13.39
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- EMCG 73.32
- CMRX 60.78
- Support Level
- EMCG $11.47
- CMRX $0.80
- Resistance Level
- EMCG $11.62
- CMRX $0.98
- Average True Range (ATR)
- EMCG 0.01
- CMRX 0.05
- MACD
- EMCG 0.01
- CMRX 0.01
- Stochastic Oscillator
- EMCG 84.62
- CMRX 83.33
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.